Bone Biologics director receives 113,896 stock options

The award carries a $0.50 exercise price and expires September 28, 2036.

Rhea-AI Filing Summary

Bone Biologics Corp director Phillip Terry Meikle II received non-employee stock options covering 113,896 common shares on September 28, 2026. They have a $0.50 exercise price, expire September 28, 2036, and generally vest in four equal quarterly installments, except as otherwise provided in the award notice. Other listed options cover 10,483 shares at $5.28, expiring June 4, 2035, and separate positions covering 4,698 and 2 shares at $11.28, expiring October 16, 2034; those options are fully exercisable as of the report date.

Insider Trade Summary

Grant/Award: 113,896 shares

Grant/Award 4 txns

Insider Meikle Phillip Terry II

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non-Employee Stock Option F1	113,896	$0.00	$0.00
holding	Non-Employee Stock Option F2	--	--	--
holding	Non-Employee Stock Option F2	--	--	--
holding	Non-Employee Stock Option F2	--	--	--

Holdings After Transaction: Non-Employee Stock Option — 129,079 contracts for 15,183 underlying shares (Direct)

Footnotes (2)

1. F1. This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments.
2. F2. This option is fully exercisable as of the date of this report.

Key Figures

Common shares underlying awarded options: 113,896 shares Award exercise price: $0.50 per share Award option expiration: September 28, 2036 +4 more

7 metrics

Common shares underlying awarded options 113,896 shares Award dated September 28, 2026.

Award exercise price $0.50 per share Non-employee stock options granted September 28, 2026.

Award option expiration September 28, 2036 Expiration date of the awarded options.

Award vesting installments Four equal quarterly installments Except as otherwise provided in the award notice.

Underlying shares in listed direct option position 10,483 shares Exercise price $5.28; expiration June 4, 2035; fully exercisable as of the report date.

Underlying shares in listed direct option position 4,698 shares Exercise price $11.28; expiration October 16, 2034; fully exercisable as of the report date.

Underlying shares in listed direct option position 2 shares Exercise price $11.28; expiration October 16, 2034; fully exercisable as of the report date.

Key Terms

Non-Employee Stock Option, exercise price, four equal quarterly installments, fully exercisable, +1 more

5 terms

Non-Employee Stock Option financial

"Non-Employee Stock Option"

exercise price financial

"exercise price of $0.5000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

four equal quarterly installments technical

"vests in four equal quarterly installments"

fully exercisable technical

"fully exercisable as of the date of this report"

Rule 16b-3 regulatory

"a transaction exempt under Rule 16b-3"

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Which plan covers Phillip Terry Meikle II's BBLG option grant?

The options were granted under the Bone Biologics Corporation 2015 Equity Incentive Plan. The award generally vests in four equal quarterly installments, except as otherwise provided in the award notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/30/2026 - 05:09 PM Accepted by SEC EDGAR 09/30/2026 - 05:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Meikle Phillip Terry II

(Last) (First) (Middle)

C/O BONE BIOLOGICS CORP

2 BURLINGTON WOODS DR. SUITE 100

(Street)

BURLINGTON MASSACHUSETTS 01803

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bone Biologics Corp [ BBLG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Employee Stock Option	$0.5	09/28/2026		A		113,896		(1)	09/28/2036	Common Stock	113,896	$0	113,896	D
Non-Employee Stock Option	$5.28							(2)	06/04/2035	Common Stock	10,483		10,483	D
Non-Employee Stock Option	$11.28							(2)	10/16/2034	Common Stock	4,698		4,698	D
Non-Employee Stock Option	$11.28							(2)	10/16/2034	Common Stock	2		2	D

Explanation of Responses:

1. This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments.

2. This option is fully exercisable as of the date of this report.

	/s/ Phillip Meikle	09/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)